Journal of Antimicrobial Chemotherapy
The Journal of Antimicrobial Chemotherapy (JAC) is among the foremost international journals in antimicrobial research. Our readership includes representatives of academia, industry and health services, and includes those who are influential in formulary decisions. JAC is included in over 3700 consortia subscriptions that span institutions across the globe.
Published monthly, the Journal features original articles on the laboratory aspects and clinical use of antimicrobials including antibacterial, antiviral, antifungal, and antiprotozoal agents and each issue contains Editor’s Choice papers, which are open access to all, offering true value to the scientific, research and healthcare communities.
In addition to the wealth of primary papers, the journal carries review articles offering in-depth discussion on matters of topical concern. Lively leading articles offer incisive coverage of recent advances and controversies.
2016 marks the 40th anniversary of JAC and we have compiled a timeline to commemorate this landmark occasion. The timeline highlights key milestones and articles in JAC’s history, including top cited, top downloaded and articles with high Altmetric scores. All articles featured in the timeline will be freely accessible until the 31st May 2016. Click here to start exploring an interactive timeline of JAC key moments and access to a series of historical and recent papers in celebration.
Notice: The BSAC Council, Journal of Antimicrobial Chemotherapy and Oxford University Press would like to reassure its members, and the Journal its authors and readers, that they do not send out unsolicited e-mails inviting submissions to the Journal. Invitations to submit articles are made, in person, solely by the Editor-in-Chief or a member of the editorial board authorized to do so.
Dilip Nathwani BSAC President
J Peter Donnelly Editor-in-Chief Journal of Antimicrobial Chemotherapy
Phil Bishop Senior Publisher, Clinical Medicine, Oxford University Press